Skip to main content

Advertisement

Springer Nature Link
Log in

The current spectrum of infection in cancer patients with chemotherapy related neutropenia

  • Review
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Despite advancements in the treatment and supportive care of patients with malignant disorders, neutropenia remains the major side effect of most antineoplastic regimens. Infections occur frequently in neutropenic patients and are associated with considerable morbidity and mortality. The spectrum of infection continues to change, and is influenced by various factors including local epidemiology, the use of chemoprophylaxis, and the use of central venous catheters and other medical devices. Bacterial infections are common in the early stages of neutropenia, with fungal infections emerging if neutropenia persists beyond 7–10 days. Gram-positive organisms cause most bacteremic infections (although this trend appears to be changing), whereas infections at other sites are often caused by Gram-negative bacilli or are polymicrobial, especially if deep tissue infection is present. Candida spp., and Aspergillus spp., remain the most common fungal pathogens, although several opportunistic fungi have emerged. Resistance to antimicrobial and antifungal agents commonly used for the prevention and treatment of infections in neutropenic patients has become a significant problem. The prompt administration of appropriate, empiric, antimicrobial therapy, prior to the availability of microbiological culture results, is the standard of care. Up to date knowledge of the spectrum of infection and local susceptibility/resistance patterns, is critical. In this report, we describe the current spectrum of infection in patients with malignancies and neutropenia, and emphasize the fact that local and geographic differences are not infrequent. We recommend that individual institutions conduct periodic epidemiological surveys in order to have the latest data available for the optimal management of their patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.

    Article  PubMed  Google Scholar 

  2. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228–37.

    Article  PubMed  Google Scholar 

  3. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56–93.

    Article  PubMed  Google Scholar 

  4. Chrischilles EA, Link BK, Scott SD, Delgado DJ, Fridman M. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin’s lymphoma. Cancer Control. 2003;10(5):396–403.

    PubMed  Google Scholar 

  5. Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(6):794–810.

    Article  PubMed  Google Scholar 

  6. Baden LR, Bensinger W, Angarone M, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. 2012;10(11):1412–45.

    CAS  PubMed  Google Scholar 

  7. Montassier E, Batard E, Gastinne T, Potel G, de La Cochetière MF. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 2013;32(7):841–50.

    Article  CAS  PubMed  Google Scholar 

  8. Rolston KV, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis. 2007;45(2):228–33.

    Article  PubMed  Google Scholar 

  9. Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agent. 2007;30(Suppl 1):S51–9.

    Article  CAS  Google Scholar 

  10. Nesher L, Rolston KVI. Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy. Clin Infect Dis. 2013;56(5):711–7.

    Article  PubMed  Google Scholar 

  11. Zell JA, Chang JC. Neoplastic fever: a neglected paraneoplastic syndrome. Support Care Cancer. 2005;13(11):870–7.

    Article  PubMed  Google Scholar 

  12. Sandoval C, Sinaki B, Weiss R, et al. Urinary tract infections in pediatric oncology patients with fever and neutropenia. Pediatr Hematol Oncol. 2012;29(1):68–72.

    Article  PubMed  Google Scholar 

  13. Cecinati V, Brescia L, Tagliaferri L, Giordano P, Esposito S. Catheter-related infections in pediatric patients with cancer. Eur J Clin Microbiol Infect Dis. 2012;31(11):2869–77.

    Article  CAS  PubMed  Google Scholar 

  14. Yadegarynia D, Tarrand J, Raad I, Rolston K. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis. 2003;37(8):1144–5.

    Article  CAS  PubMed  Google Scholar 

  15. Singh R, Ray P, Das A, Sharma M. Penetration of antibiotics through Staphylococcus aureus and Staphylococcus epidermidis biofilms. J Antimicrob Chemother. 2010;65(9):1955–8.

    Article  CAS  PubMed  Google Scholar 

  16. Wisplinghoff H, Seifert H. Wenzel RP. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States: Edmond MB; 2003.

    Google Scholar 

  17. Aslan S, Citak EC, Yis R, Degirmenci S, Arman D. Bacterial spectrum and antimicrobial susceptibility pattern of bloodstream infections in children with febrile neutropenia: experience of single center in southeast of Turkey. Indian J Microbiol. 2012;52(2):203–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999;29(3):490–4.

    Article  CAS  PubMed  Google Scholar 

  19. Elting LS, Bodey GP, Fainstein V. Polymicrobial septicemia in the cancer patient. Medicine (Baltimore). 1986;65(4):218–25.

    Article  CAS  Google Scholar 

  20. Gudiol C, Bodro M, Simonetti A, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect. 2013;19(5):474–9.

    Article  CAS  PubMed  Google Scholar 

  21. Samonis G, Vardakas KZ, Maraki S, et al. A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies. Support Care Cancer. 2013;21(9):2521–2526.

    Article  PubMed  Google Scholar 

  22. Cortés JA, Cuervo S, Gómez CA, Bermúdez D, Martínez T, Arroyo P. Febrile neutropenia in the tropics: a description of clinical and microbiological findings and their impact on inappropriate therapy currently used at an oncological reference center in Colombia. Biomedica. 2013;33(1):70–7.

    PubMed  Google Scholar 

  23. Kang CI, Song JH, Chung DR, et al. Bloodstream infections in adult patients with cancer: clinical features and pathogenic significance of Staphylococcus aureus bacteremia. Support Care Cancer. 2012;20(10):2371–8.

    Article  PubMed  Google Scholar 

  24. Ram R, Farbman L, Leibovici L, et al. Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients. Int J Antimicrob Agents. 2012;40(2):123–6.

    Article  CAS  PubMed  Google Scholar 

  25. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009;49(1):1–45.

    Article  CAS  PubMed  Google Scholar 

  26. Kleiner E, Monk AB, Archer GL, Forbes BA. Clinical significance of Staphylococcus lugdunensis isolated from routine cultures. Clin Infect Dis. 2010;51(7):801–3.

    Article  PubMed  Google Scholar 

  27. Kjellander C, Björkholm M, Cherif H, Kalin M, Giske CG. Hematological: low all-cause mortality and low occurrence of antimicrobial resistance in hematological patients with bacteremia receiving no antibacterial prophylaxis: a single-center study. Eur J Haematol. 2012;88(5):422–30.

    Article  CAS  PubMed  Google Scholar 

  28. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42(6):2398–402.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Safdar A, Rolston KV. Vancomycin tolerance, a potential mechanism for refractory gram-positive bacteremia observational study in patients with cancer. Cancer. 2006;106(8):1815–20.

    Article  CAS  PubMed  Google Scholar 

  30. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755–71.

    Article  PubMed  Google Scholar 

  31. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55.

    Article  PubMed  Google Scholar 

  32. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992;14(6):1201–7.

    Article  CAS  PubMed  Google Scholar 

  33. Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 1994;18(1):25–31.

    Article  CAS  PubMed  Google Scholar 

  34. Han XY, Kamana M, Rolston KV. Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases. J Clin Microbiol. 2006;44(1):160–5.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Rolston KV, Jiang Y, Matar M. VRE fecal colonization/infection in cancer patients. Bone Marrow Transpl. 2007;39(9):567–8.

    Article  CAS  Google Scholar 

  36. Liss BJ, Vehreschild JJ, Cornely OA, et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2012;40(6):613–619.

    Article  CAS  PubMed  Google Scholar 

  37. Mihu CN, Rhomberg PR, Jones RN, Coyle E, Prince RA, Rolston KV. Escherichia coli resistance to quinolones at a comprehensive cancer center. Diagn Microbiol Infect Dis. 2010;67(3):266–9.

    Article  CAS  PubMed  Google Scholar 

  38. Kim SH, Kwon JC, Choi SM, et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome. Ann Hematol. 2013;92(4):533–41.

    Article  PubMed  Google Scholar 

  39. Patel G, Bonomo RA. “Stormy waters ahead”: global emergence of carbapenemases. Front Microbiol. 2013;4:48.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Pillai DR, McGeer A, Low DE. New Delhi metallo-β-lactamase-1 in Enterobacteriaceae: emerging resistance. CMAJ. 2011;183(1):59–64.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Cattaneo C, Antoniazzi F, Casari S, et al. P. aeruginosa bloodstream infections among hematological patients: an old or new question? Ann Hematol. 2012;91(8):1299–304.

    Article  PubMed  Google Scholar 

  42. Rolston KV, Kontoyiannis DP, Yadegarynia D, Raad II. Nonfermentative gram-negative bacilli in cancer patients: increasing frequency of infection and antimicrobial susceptibility of clinical isolates to fluoroquinolones. Diagn Microbiol Infect Dis. 2005;51(3):215–8.

    Article  CAS  PubMed  Google Scholar 

  43. Rolston KV, Tarrand JJ. Pseudomonas aeruginosa—still a frequent pathogen in patients with cancer: 11-year experience at a comprehensive cancer center. Clin Infect Dis. 1999;29(2):463–4.

    Article  CAS  PubMed  Google Scholar 

  44. Toleman MA, Rolston K, Jones RN, Walsh TR. blaVIM-7, an evolutionarily distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob Agents Chemother. 2004;48(1):329–32.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Ohmagari N, Hanna H, Graviss L, et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer. 2005;104(1):205–12.

    Article  PubMed  Google Scholar 

  46. Demiraslan H, Sevim M, Pala Ç, et al. Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology-oncology patients. Int J Hematol. 2013;97(3):414–20.

    Article  CAS  PubMed  Google Scholar 

  47. Krueger TS, Clark EA, Nix DE. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn Microbiol Infect Dis. 2001;41(1–2):71–8.

    Article  CAS  PubMed  Google Scholar 

  48. Sood P, Seth T, Kapil A, et al. Emergence of multidrug resistant acinetobacter blood stream infections in febrile neutropenia patients with haematological cancers and bone marrow failure syndromes. J Indian Med Assoc. 2012;110(7):439–44.

    PubMed  Google Scholar 

  49. El-Sharif A, Elkhatib WF, Ashour HM. Nosocomial infections in leukemic and solid-tumor cancer patients: distribution, outcome and microbial spectrum of anaerobes. Future Microbiol. 2012;7(12):1423–9.

    Article  CAS  PubMed  Google Scholar 

  50. Chen CY, Cheng A, Huang SY, et al. Clinical and microbiological characteristics of perianal infections in adult patients with acute leukemia. PLoS One. 2013;8(4):e60624.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. Brook I, Frazier EH. Aerobic and anaerobic infection associated with malignancy. Support Care Cancer. 1998;6(2):125–31.

    Article  CAS  PubMed  Google Scholar 

  52. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–100.

    Article  PubMed  Google Scholar 

  53. Colombo AL, Perfect J, DiNubile M, et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis. 2003;22(8):470–4.

    Article  CAS  PubMed  Google Scholar 

  54. Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One. 2011;6(9):e24198.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  55. Maschmeyer G. The changing epidemiology of invasive fungal infections: new threats. Int J Antimicrob Agents. 2006;27(Suppl 1):3–6.

    Article  PubMed  Google Scholar 

  56. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008;112(11):2493–9.

    Article  PubMed  Google Scholar 

  57. Steinbach WJ, Marr KA, Anaissie EJ, et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect. 2012;65(5):453–64.

    Article  PubMed  Google Scholar 

  58. Girmenia C, Pagano L, Martino B, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol. 2005;43(4):1818–28.

    Article  PubMed Central  PubMed  Google Scholar 

  59. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med. 2004;350(9):950–2.

    Article  CAS  PubMed  Google Scholar 

  60. Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998–2009. J Infect. 2010;60(5):331–7.

    Article  PubMed  Google Scholar 

  61. Lamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989 to 2006. Clin Infect Dis. 2006;43(12):1580–4.

    Article  PubMed  Google Scholar 

  62. Saral R, Ambinder RF, Burns WH, et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med. 1983;99(6):773–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. (Unit 1460), Houston, TX, 77030, USA

    Lior Nesher & Kenneth V. I. Rolston

Authors
  1. Lior Nesher
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Kenneth V. I. Rolston
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Kenneth V. I. Rolston.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nesher, L., Rolston, K.V.I. The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection 42, 5–13 (2014). https://doi.org/10.1007/s15010-013-0525-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-013-0525-9

Keywords